Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 2:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 475 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Menopausal Women Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Investigate Hepatic Impairment on PK, Safety, Tolerability of Camizestrant in Post-Menopausal Female Subjects

NCT05790304
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Camizestrant
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
50 Years to 75 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Oct 24, 2026, 2:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Impact of Egg Consumption on Carotenoid and Vitamin D Bioavailability in Pre- and Post-menopausal Women

NCT02679794
View directory record Official record
Conditions
Menopause
Interventions
Egg consumption, Control
Behavioral
Lead sponsor
Purdue University
Other
Eligibility
19 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 11, 2018 · Synced Oct 24, 2026, 2:02 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Open-Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) 100mg On The Pharmacokinetics Of Tamoxifen When Coadministered To Healthy Post-Menopausal Female Subjects

NCT01189500
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Tamoxifen, Tamoxifen and Desvenlafaxine Succinate Sustained Release
Drug
Lead sponsor
Pfizer
Industry
Eligibility
45 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
2
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 7, 2011 · Synced Oct 24, 2026, 2:02 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer

NCT02296801
View directory record Official record
Conditions
Breast Cancer, Breast Carcinoma, Breast Tumors
Interventions
Letrozole, palbociclib
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older · Female only
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
19
States / cities
Long Beach, California • Miami, Florida • Decatur, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2022 · Synced Oct 24, 2026, 2:02 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Hormone Replacement and Neural Cardiovascular Control in Postmenopausal Women

NCT01633814
View directory record Official record
Conditions
Menopause, Aging, Blood Pressure
Interventions
Transdermal estradiol, Placebo
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Oct 24, 2026, 2:02 AM EDT
Completed Phase 3 Interventional Results available

Dehydroepiandrosterone (DHEA) Against Vaginal Atrophy

NCT01358760
View directory record Official record
Conditions
Vaginal Atrophy
Interventions
Placebo, DHEA
Drug
Lead sponsor
EndoCeutics Inc.
Industry
Eligibility
40 Years to 75 Years · Female only
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
32
States / cities
Montgomery, Alabama • Tucson, Arizona • Little Rock, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2017 · Synced Oct 24, 2026, 2:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Moringa Oleifera on Bone Density

NCT03026660
View directory record Official record
Conditions
Osteoporosis, Osteopenia, Postmenopausal Osteoporosis
Interventions
Moringa Oleifera, Cabbage Placebo
Dietary Supplement
Lead sponsor
Appalachian State University
Other
Eligibility
60 Years to 70 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Boone, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 20, 2017 · Synced Oct 24, 2026, 2:02 AM EDT
Recruiting Not applicable Interventional

Improving Outcomes in Early Menopause After Cancer

NCT06982677
View directory record Official record
Conditions
Early Menopause, Cancer, Premature Menopause, Surgical Menopause
Interventions
Nurse Navigator Intervention, Education Control
Behavioral · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 24, 2026, 2:02 AM EDT
Recruiting Not applicable Interventional

A Clinical Study to Assess Histological Changes From Treatment of Poly L-lactic Acid Biostimulator on Women at Various Menopausal Stages

NCT07342400
View directory record Official record
Conditions
Cheek Wrinkles, Menopausal Women
Interventions
Sculptra®
Device
Lead sponsor
Galderma R&D
Industry
Eligibility
22 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Miami, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Oct 24, 2026, 2:02 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Telapristone Acetate (Proellex®) in the Treatment of Pre-Menopausal Women With Confirmed, Symptomatic Endometriosis

NCT01728454
View directory record Official record
Conditions
Endometriosis
Interventions
Placebo, Telapristone acetate
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 47 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
10
States / cities
Tucson, Arizona • Little Rock, Arkansas • Jacksonville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 24, 2026, 2:02 AM EDT
Completed Phase 1 Interventional

A Phase 1b Study of TAK-700 in Postmenopausal Women With Hormone-receptor Positive Metastatic Breast Cancer

NCT01808040
View directory record Official record
Conditions
Post Menopausal, Hormone Receptor Positive Breast Cancer
Interventions
TAK700
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Oct 24, 2026, 2:02 AM EDT
Completed Phase 3 Interventional

Study to Assess the Efficacy/Safety of Transdermal Testosterone Patches in Naturally Menopausal Women With Low Libido

NCT00349791
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder (HSDD)
Interventions
Testosterone Transdermal System, Placebo patch
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
40 Years to 70 Years · Female only
Enrollment
549 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 17, 2013 · Synced Oct 24, 2026, 2:02 AM EDT
No Longer Available No phase listed Expanded access

Expanded Access Study Of Palbociclib (PD-0332991) In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive, Her2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate

NCT02142868
View directory record Official record
Conditions
Advanced Breast Cancer (Female)
Interventions
Palbociclib, Letrozole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
44
States / cities
Bakersfield, California • Washington D.C., District of Columbia • Duluth, Georgia + 30 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2018 · Synced Oct 24, 2026, 2:02 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Assessing Fertility Potential in Female Cancer Survivors

NCT01143844
View directory record Official record
Conditions
Effects of Chemotherapy
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
11 Years to 50 Years · Female only
Enrollment
391 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2020
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Radnor, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Oct 24, 2026, 2:02 AM EDT
Completed Phase 2 Interventional

Treatment of Mid-Life-Related Mood Disorders

NCT00001487
View directory record Official record
Conditions
Depressive Disorder, Mood Disorder
Interventions
Dehydroepiandrosterone
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 24, 2026, 2:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Determine the Effect of Multiple Oral Doses and Regimens of KD025 in Healthy Male and Post-menopausal Female Subjects

NCT05918588
View directory record Official record
Conditions
Immune System Disorder (Healthy Volunteer)
Interventions
Belumosudil mesylate, Placebo
Drug
Lead sponsor
Kadmon, a Sanofi Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Oct 24, 2026, 2:02 AM EDT
Terminated Phase 2 Interventional Results available

Study Evaluating Bosutinib-Exemestane Combination Vs Exemestane Alone in Post Menopausal Women With Breast Cancer

NCT00793546
View directory record Official record
Conditions
Advanced Breast Cancer
Interventions
Bosutinib, Exemestane
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
11
States / cities
Lake Worth, Florida • Joliet, Illinois • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2012 · Synced Oct 24, 2026, 2:02 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Ovarian Hormone Regulation of Central and Cerebrovascular Hemodynamics (NoMEN Study)

NCT05057546
View directory record Official record
Conditions
Menopause, Estrogen Deficiency, Women, Aging
Interventions
GnRH antagonist
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Oct 24, 2026, 2:02 AM EDT
Completed Phase 3 Interventional Results available

Endometrial Safety Study

NCT00522873
View directory record Official record
Conditions
Postmenopause
Interventions
0.25mg DRSP / 0.5mg E2 (BAY86-4891), 0.5mg NETA / 1.0mg E2 (Activella)
Drug
Lead sponsor
Bayer
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
662 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
17
States / cities
Chandler, Arizona • San Diego, California • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2014 · Synced Oct 24, 2026, 2:02 AM EDT
Completed Phase 4 Interventional Results available

Effects of Teriparatide or Zoledronic Acid Treatment on Bone in Postmenopausal Osteoporotic Women

NCT00927186
View directory record Official record
Conditions
Osteoporosis, Post-menopausal
Interventions
Teriparatide, Zoledronic Acid
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years to 89 Years · Female only
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
9
States / cities
Lakewood, Colorado • Atlanta, Georgia • Gainesville, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2013 · Synced Oct 24, 2026, 2:02 AM EDT
Completed Phase 2 Interventional Results available

Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen

NCT00764322
View directory record Official record
Conditions
Breast Cancer, Menopausal Symptoms
Interventions
tamoxifen citrate, gene expression analysis, pharmacogenomic studies, questionnaire administration, quality-of-life assessment
Drug · Genetic · Other + 1 more
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
21 Years to 120 Years · Female only
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
7
States / cities
Chapel Hill, North Carolina • Charlotte, North Carolina • Durham, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Oct 24, 2026, 2:02 AM EDT
Not listed Phase 3 Interventional

Examining Effects of Intrarosa in Women With Genitourinary Syndrome of Menopause/Vulvovaginal Atrophy

NCT03782480
View directory record Official record
Conditions
Menopause, Genitourinary Syndrome of Menopause, Vulvovaginal Atrophy, Menopause Syndrome, Dyspareunia
Interventions
Intrarosa, Placebos
Drug
Lead sponsor
Center for Vulvovaginal Disorders
Other
Eligibility
40 Years to 80 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Washington D.C., District of Columbia • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 31, 2019 · Synced Oct 24, 2026, 2:02 AM EDT
Completed Phase 1 Interventional Results available

A Study of the Safety and Effect of Repeated Administration of G-CSF on Hot Flashes in Postmenopausal Women

NCT03640754
View directory record Official record
Conditions
Postmenopausal Symptoms
Interventions
G-CSF, Placebo/Saline
Biological · Other
Lead sponsor
MenoGeniX, Inc.
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Aurora, Colorado • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Oct 24, 2026, 2:02 AM EDT
Recruiting Not applicable Interventional

Study on Allopregnanolone and Depression in Women Across the Menopause Transition

NCT06238700
View directory record Official record
Conditions
Depression
Interventions
pregnenolone, placebo
Dietary Supplement · Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
40 Years to 60 Years · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 24, 2026, 2:02 AM EDT